TISIDB

Summary
Symbol	MBD1
Name	methyl-CpG binding domain protein 1
Aliases	CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Nucleus matrix Nucleus speckle. Chromosome. Note=Colocalizes with the Ten-1 ICD form of TENM1 in foci associated with the nuclear matrix (By similarity). Nuclear, in a punctate pattern. Associated with euchromatic regions of the chromosomes, with pericentromeric regions on chromosome 1 and with telomeric regions from several chromosomes.
Domain	PF01429 Methyl-CpG binding domain PF02008 CXXC zinc finger domain
Function	Transcriptional repressor that binds CpG islands in promoters where the DNA is methylated at position 5 of cytosine within CpG dinucleotides. Binding is abolished by the presence of 7-mG that is produced by DNA damage by methylmethanesulfonate (MMS). Acts as transcriptional repressor and plays a role in gene silencing by recruiting AFT7IP, which in turn recruits factors such as the histone methyltransferase SETDB1. Probably forms a complex with SETDB1 and ATF7IP that represses transcription and couples DNA methylation and histone 'Lys-9' trimethylation. Isoform 1 and isoform 2 can also repress transcription from unmethylated promoters.

> Gene Ontology [ TOP ]
Biological Process	GO:0006304 DNA modification GO:0006305 DNA alkylation GO:0006306 DNA methylation GO:0006342 chromatin silencing GO:0006346 methylation-dependent chromatin silencing GO:0007507 heart development GO:0007568 aging GO:0009991 response to extracellular stimulus GO:0010001 glial cell differentiation GO:0010721 negative regulation of cell development GO:0014013 regulation of gliogenesis GO:0014014 negative regulation of gliogenesis GO:0016458 gene silencing GO:0031667 response to nutrient levels GO:0032259 methylation GO:0032355 response to estradiol GO:0040029 regulation of gene expression, epigenetic GO:0042063 gliogenesis GO:0042220 response to cocaine GO:0043279 response to alkaloid GO:0043414 macromolecule methylation GO:0044030 regulation of DNA methylation GO:0044728 DNA methylation or demethylation GO:0045685 regulation of glial cell differentiation GO:0045686 negative regulation of glial cell differentiation GO:0045814 negative regulation of gene expression, epigenetic GO:0048708 astrocyte differentiation GO:0048710 regulation of astrocyte differentiation GO:0048712 negative regulation of astrocyte differentiation GO:0050768 negative regulation of neurogenesis GO:0051052 regulation of DNA metabolic process GO:0051961 negative regulation of nervous system development
Molecular Function	GO:0003682 chromatin binding GO:0008327 methyl-CpG binding GO:0010385 double-stranded methylated DNA binding
Cellular Component	GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0016363 nuclear matrix GO:0016604 nuclear body GO:0016607 nuclear speck GO:0034399 nuclear periphery GO:0044454 nuclear chromosome part

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	MBD1
Name	methyl-CpG binding domain protein 1
Aliases	CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MBD1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MBD1
Name	methyl-CpG binding domain protein 1
Aliases	CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MBD1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MBD1
Name	methyl-CpG binding domain protein 1
Aliases	CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MBD1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.019	0.912
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.015	0.994
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.043	0.976
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.387	0.318
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.565	0.801
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.166	0.955
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.174	0.624
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.249	0.872
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.073	0.967
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.318	0.822
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.86	0.674
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.109	0.114

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MBD1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	2.7	12.1	0.0439
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	1.7	13.1	0.032
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	5.9	3.6	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	0	25	0.473
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MBD1
Name	methyl-CpG binding domain protein 1
Aliases	CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MBD1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MBD1
Name	methyl-CpG binding domain protein 1
Aliases	CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MBD1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MBD1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MBD1
Name	methyl-CpG binding domain protein 1
Aliases	CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MBD1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MBD1
Name	methyl-CpG binding domain protein 1
Aliases	CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MBD1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MBD1
Name	methyl-CpG binding domain protein 1
Aliases	CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MBD1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MBD1
Name	methyl-CpG binding domain protein 1
Aliases	CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MBD1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MBD1